Merck, SML0140-25MG, BV02

Application
BV02, an inhibitor of the 14-3-3 scaffolding protein docking sites, may be used to study the roles and functions of 14-3-3 scaffolding proteins in signaling pathways involved in the cell cycle, and processes such as apoptosis, stress response, and malignant cell transformation.
BV02 has been used to study the effects of 14-3-3σ on P-glycoprotein and pregnane X receptor protein xpression. It has also been used as a control in studying BAP1 (BRCA1 (breast cancer gene)-associated protein 1) inducing cell death via interaction with 14-3-3 in neuroblastoma.
Biochem/physiol Actions
BV02 is an inhibitor of the 14-3-3 scaffolding proteins docking site.
BV02 is an inhibitor of the 14-3-3 scaffolding proteins docking site. BV02 promotes the apoptotic death of cells expressing either wt Bcr-Abl construct or T315I mutation. It induces apoptosis by c-Abl release from 14-3-3? and re-location to nuclear compartment and at mitochondrial membranes.